Related content

Predicting the Risk of Cardiovascular Disease: Where Does Lipoprotein-Associated Phospholipase A2 Fit In?

By Khuseyinova Natalie   Koenig Wolfgang  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 4, 2007-01 ,pp. : 203-217

Adis International

Access to resources Recommend Favorite

Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 9, Iss. 5, 2011-05 ,pp. : 1056-1066

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals

By Rosendo Alexandre   Lima Luciana   Dal-Pizzol Felipe   Almeida Silvana  

Inflammation, Vol. 33, Iss. 4, 2010-08 ,pp. : 244-250

Springer Publishing Company

Access to resources Recommend Favorite

Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications

By Holt Tim A   Thorogood Margaret   Griffiths Frances   Munday Stephen   Stables David  

British Journal of General Practice, Vol. 58, Iss. 552, 2008-07 ,pp. : 495-498

Royal College of General Practitioners

Access to resources Recommend Favorite

Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease

By Halvorsen B.   Sagen Lund   Ueland T.   Aukrust P.   Tonstad S.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 6, 2007-01 ,pp. : 604-611

Informa Healthcare

Access to resources Recommend Favorite